A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization

Shanthi P. Kanthala; Yong-Yu Liu; Shubhadra N. Singh; Rushikesh Sable; Sandeep Pallerla; Seetharama D. Jois

doi:10.18632/oncotarget.19013

journal article Open Access Jul 05, 2017

A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization

Shanthi P. Kanthala Yong-Yu Liu Shubhadra N. Singh Rushikesh Sable Sandeep Pallerla Seetharama D. Jois

Oncotarget Vol. 8 No. 43 pp. 74244-74262 · Impact Journals, LLC

View at Publisher Save 10.18632/oncotarget.19013

Topics

No keywords indexed for this article. Browse by subject →

References

61

[1]

Bennasroune "Role of ErbB Receptors in Cancer Cell Migration and Invasion" Front Pharmacol (2015) 10.3389/fphar.2015.00283

[2]

Stern "A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy" Cancer Res (2008) 10.1158/0008-5472.can-08-0380

[3]

Gianni "Treatment of HER2-positive breast cancer: current status and future perspectives" Nat Rev Clin Oncol (2012) 10.1038/nrclinonc.2011.177

[4]

Sok "Signaling through the epidermal growth factor receptor during the development of malignancy" Pharmacol Ther (2004) 10.1016/j.pharmthera.2004.01.002

[5]

Ferguson "Structure-based view of epidermal growth factor receptor regulation" Annu Rev Biophys (2008) 10.1146/annurev.biophys.37.032807.125829

[6]

Ferguson "Active and inactive conformations of the epidermal growth factor receptor" Biochem Soc Trans (2004) 10.1042/bst0320742

[7]

Resat "Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response" Biophys J (2006) 10.1529/biophysj.105.080580

[8]

Cappuzzo "Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer" Oncogene (2009) 10.1038/onc.2009.199

[9]

Danenberg "Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival" Clin Cancer Res (2001)

[10]

Pao "New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer" Clin Cancer Res (2011) 10.1158/1078-0432.ccr-10-2571

[11]

Ozyilkan "The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients" J Exp Clin Cancer Res (2009) 10.1186/1756-9966-28-97

[12]

Chang "HER2 inhibition: from discovery to clinical practice" Clin Cancer Res (2007) 10.1158/1078-0432.ccr-06-2405

[13]

Schiff "Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy" J Natl Cancer Inst (2007) 10.1093/jnci/djk151

[14]

Mellman "Antibody therapeutics in cancer" Science (2013) 10.1126/science.1241145

[15]

Swain "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3" Nat Rev Cancer (2009) 10.1038/nrc2656

[16]

Kurtz "Pertuzumab: development beyond breast cancer" Anticancer Res (2014)

[17]

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Hyun-Soo Cho, Karen Mason, Kasra X. Ramyar et al.

Nature 2003 10.1038/nature01392

[18]

Demichele "Accelerated Approval for Pertuzumab in the Neoadjuvant Setting: Winds of Change?" Clin Cancer Res (2014) 10.1158/1078-0432.ccr-13-3131

[19]

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Matthew C Franklin, Kendall D Carey, Felix F Vajdos et al.

Cancer Cell 2004 10.1016/s1535-6108(04)00083-2

[20]

Esteva "Herceptin: mechanisms of action and resistance" Cancer Lett (2006) 10.1016/j.canlet.2005.01.041

[21]

Naisbitt "Challenges and approaches for the development of safer immunomodulatory biologics" Nat Rev Drug Discov (2013) 10.1038/nrd3974

[22]

Jois "Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors" Future Oncol (2015) 10.2217/fon.14.312

[23]

Hruby "Designing peptide receptor agonists and antagonists" Nat Rev Drug Discov (2002) 10.1038/nrd939

[24]

Satyanarayanajois "Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines" MedChemComm (2011) 10.1039/c1md00126d

[25]

Satyanarayanajois "A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein" J Biomol Struct Dyn (2010) 10.1080/07391102.2010.10507360

[26]

Jois "Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer" Chem Biol Drug Des (2014) 10.1111/cbdd.12453

[27]

Satyanarayanajois "Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3" Biopolymers (2014) 10.1002/bip.22441

[28]

Kotze "Oral delivery of peptide drugs: barriers and developments" BioDrugs (2005) 10.2165/00063030-200519030-00003

[29]

McGregor "Discovering and improving novel peptide therapeutics" Curr Opin Pharmacol (2008) 10.1016/j.coph.2008.06.002

[30]

Hudecz "Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide" Proc Natl Acad Sci USA (2005) 10.1073/pnas.0407677102

[31]

Satyanarayanajois "Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic" J Biomol Struct Dyn (2012) 10.1080/07391102.2012.687525

[32]

Balaram "Crystal structures of peptide enantiomers and racemates: probing conformational diversity in heterochiral Pro-Pro sequences" Biopolymers (2008) 10.1002/bip.20982

[33]

Balaram "Designed peptides with homochiral and heterochiral diproline templates as conformational constraints" Chemistry (2008) 10.1002/chem.200702029

[34]

Protein detection using proximity-dependent DNA ligation assays

Simon Fredriksson, Mats Gullberg, Jonas Jarvius et al.

Nature Biotechnology 2002 10.1038/nbt0502-473

[35]

Chen "Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay" J Biol Chem (2009) 10.1074/jbc.m806516200

[36]

Zhou "Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma" Open Med (Wars) (2016) 10.1515/med-2016-0014

[37]

Karp "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC" Cancer Discov (2013) 10.1158/2159-8290.cd-13-0314

[38]

Tallarida "Quantitative methods for assessing drug synergism" Genes Cancer (2011) 10.1177/1947601912440575

[39]

Finn "Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumaband" Clin Cancer Res (2010) 10.1158/1078-0432.ccr-09-1112

[40]

Hoffman "Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability" J Med Chem (2007) 10.1021/jm070836d

[41]

Vogel "The interactions of antimicrobial peptides derived from lysozyme with model membrane systems" Biochim Biophys Acta (2005) 10.1016/j.bbamem.2004.12.004

[42]

Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

James A. Wells, Christopher L. McClendon

Nature 2007 10.1038/nature06526

[43]

Hot spots—A review of the protein–protein interface determinant amino‐acid residues

Irina S. Moreira, Pedro A. Fernandes, Maria J. Ramos

Proteins: Structure, Function, and Bioinformatics 2007 10.1002/prot.21396

[44]

Anatomy of hot spots in protein interfaces

Andrew A Bogan, Kurt S Thorn

Journal of Molecular Biology 1998 10.1006/jmbi.1998.1843

[45]

Eigenbrot "Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine" J Mol Biol (2010) 10.1016/j.jmb.2010.07.027

[46]

Springer "Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor" Mol Cell Biol (2010) 10.1128/mcb.00742-10

[47]

Tselios "Use of the 2-chlorotrityl chloride resin for microwave-assisted solid phase peptide synthesis" Biopolymers (2015) 10.1002/bip.22710

[48]

Albericio "Chlorotrityl Chloride (CTC) Resin as a Reusable Carboxyl Protecting Group" QSAR Comb Sci (2007) 10.1002/qsar.200720015

[49]

Tolliday "High-throughput assessment of Mammalian cell viability by determination of adenosine triphosphate levels" Curr Protoc Chem Biol (2010) 10.1002/9780470559277.ch100045

[50]

Koch "Application of surface plasmon resonance spectroscopy to study G-protein coupled receptor signalling" Methods Mol Biol (2010) 10.1007/978-1-60761-670-2_17

Showing 50 of 61 references

Metrics

14

Citations

61

References

Details

Published: Jul 05, 2017
Vol/Issue: 8(43)
Pages: 74244-74262

Authors

S

Shanthi P. Kanthala